In a recent article on the risk of selected gastrointestinal cancers in relation to ranitidine use, Adami and colleagues took their (seemingly “negative”) results to imply that they “should be reassuring for millions of concerned past users of ranitidine” (1). In my view, however, the study suffered from some important limitations complicating the causal-inference process and making the results much less reassuring. Although the authors state that the design of their “cohort study … emulated a randomized trial,” I do not believe the emulation attempt was successful. While using active-comparator control in nonexperimental studies does help prevent confounding, it can hardly achieve this goal as well as a trial using not only active-comparator control but also randomization coupled with blinding. Thus, a nonexperimental study aiming to minimize confounding would, in addition, require an extremely thorough statistical confounding control. However, the authors seemed to have data on only a...
Skip Nav Destination
Article navigation
1 April 2022
Letters to the Editor|
April 01 2022
“Ranitidine Use and Risk of Upper Gastrointestinal Cancers”—Letter
Igor Karp
Igor Karp
*
*Corresponding Author: Igor Karp, Department of Epidemiology and Biostatistics, Western University, London, Ontario N6G 2M1, Canada. Phone: 519-661-2111, ext. 86272; E-mail: [email protected]
Search for other works by this author on:
*Corresponding Author: Igor Karp, Department of Epidemiology and Biostatistics, Western University, London, Ontario N6G 2M1, Canada. Phone: 519-661-2111, ext. 86272; E-mail: [email protected]
Cancer Epidemiol Biomarkers Prev 2022;31:914
Received:
January 12 2022
Revision Received:
January 26 2022
Accepted:
January 28 2022
Online ISSN: 1538-7755
Print ISSN: 1055-9965
©2022 American Association for Cancer Research
2022
American Association for Cancer Research
Cancer Epidemiol Biomarkers Prev (2022) 31 (4): 914.
Article history
Received:
January 12 2022
Revision Received:
January 26 2022
Accepted:
January 28 2022
Citation
Igor Karp; “Ranitidine Use and Risk of Upper Gastrointestinal Cancers”—Letter. Cancer Epidemiol Biomarkers Prev 1 April 2022; 31 (4): 914. https://doi.org/10.1158/1055-9965.EPI-22-0045
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Pay-Per-View 24-Hour Access
$50.00
Advertisement
496
Views